PPWP
VRTX icon

Premier Path Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Premier Path Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$835K Buy
1,870
+62
+3% +$28.9K 0.11% 181
2025
Q4 		$820K Buy
1,808
+118
+7% +$50.9K 0.11% 185
2025
Q3 		$662K Sell
1,690
-145
-8% -$60.6K 0.09% 225
2025
Q2 		$817K Buy
1,835
+45
+3% +$20.7K 0.11% 190
2025
Q1 		$868K Buy
1,790
+104
+6% +$48.5K 0.14% 178
2024
Q4 		$679K Buy
1,686
+80
+5% +$37.1K 0.1% 193
2024
Q3 		$747K Buy
1,606
+28
+2% +$13.4K 0.12% 180
2024
Q2 		$740K Buy
1,578
+174
+12% +$75.5K 0.13% 173
2024
Q1 		$587K Buy
1,404
+18
+1% +$7.61K 0.11% 185
2023
Q4 		$564K Buy
+1,386
New +$512K 0.12% 175

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Premier Path Wealth Partners's VRTX Position: Q1 2026 in Review

Premier Path Wealth Partners increased its Vertex Pharmaceuticals (VRTX) stake by 3.4% in Q1 2026, buying an estimated $28.9K and bringing the position to 1,870 shares worth $835K. The position accounts for 0.11% of the portfolio, ranked #181.

Premier Path Wealth Partners first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $868K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Premier Path Wealth Partners held 1,870 shares of Vertex Pharmaceuticals worth $835K as of Q1 2026.
  • Premier Path Wealth Partners bought 62 Vertex Pharmaceuticals shares in Q1 2026, an estimated $28.9K.
  • Vertex Pharmaceuticals made up 0.11% of Premier Path Wealth Partners's portfolio in Q1 2026, its #181 holding.
  • Premier Path Wealth Partners first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • Premier Path Wealth Partners's Vertex Pharmaceuticals position peaked at $868K in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Premier Path Wealth Partners's 13F filing for Q1 2026, filed 23 Apr 2026.